Idorsia Ltd. · SIX:IDIA
Idorsia — FY2019 Earnings Presentation
23 slides from Idorsia's earnings presentation, Feb 6, 2020
Slide 1: Full Year 2019 Financial Reporting
Financial Reporting 20 FULL YEAR 19
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: CEO quote on 2020 outlook
“Since the results of the daridorexant program are just months away, 2020 promises to be every bit as exciting as 2019.” Jean-Paul Clozel Chief Executive Officer 3 Full Year 2019 Financial Reporting | February 6, 2020
Slide 4: 2019 Highlights
Advancing our clinical programs 2019 HIGHLIGHTS Engaging with the expert community Delivering Building our innovation commercial capabilities 4 Full Year 2019 Financial Reporting | February 6, 2020
Slide 5: Clinical development pipeline
Clinical development pipeline Compound Mechanism of Action Target Indication Status Daridorexant Dual orexin receptor antagonist Insomnia Phase 3 – recruitment complete Aprocitentan* Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Vasospasm associated with aneurysmal Cl
Slide 6: Late-stage assets
Late-stage assets Compound Mechanism of Action Target Indication Status Daridorexant Dual orexin receptor antagonist Insomnia Phase 3 – recruitment complete Aprocitentan* Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Vasospasm associated with aneurysmal Clazosentan En
Slide 7: Daridorexant in insomnia
Daridorexant in insomnia A dual orexin receptor antagonist with Phase 2 data presented the potential to deliver sleep onset • Oral and poster presentations at and maintenance, with a duration of the annual SLEEP meeting 2019 action designed not to exceed a attended by around 5,000 normal night. dele
Slide 8: Clazosentan in cerebral vasospasm
Clazosentan in cerebral vasospasm A selective endothelin (ETA) receptor antagonist being Registration studies in Japan developed as an intravenous • Evaluating reduction of infusion for the prevention vasospasm, and vasospasm- of clinical deterioration related morbidity and mortality following aSAH
Slide 9: Lucerastat in Fabry disease
Lucerastat in Fabry disease A glucosylceramide synthase Phase 3 study ongoing inhibitor, developed as an oral • Lucerastat acts by reducing the monotherapy, offering a new damaging build-up of lipids which is treatment approach for all responsible for all the symptoms of Fabry disease patients livin
Slide 10: Aprocitentan in resistant hypertension
Aprocitentan in resistant hypertension An orally active dual endothelin receptor antagonist, which is being Phase 2 data presented investigated for patients whose • Oral presentation at the European blood pressure is uncontrolled Society of Cardiology (ESC) despite the use of at least three Congress
Slide 11: Mid-stage assets
Mid-stage assets Compound Mechanism of Action Target Indication Status Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2 Selatogrel P2Y12 receptor antagonist Suspected acute myocardial infarction Phase 2 – complete ACT-774312 CRTH2 receptor antagonist Nasal polyposis Phase 2 11
Slide 12: Cenerimod in SLE
Cenerimod in SLE A potent, selective sphingosine-1- phosphate receptor 1 (S1P1) Phase 2 data presented modulator, which potentially offers a • Oral and poster presentations novel approach for systemic lupus at the annual meeting 2019 of erythematosus (SLE) – a disease the American College of Rheumat
Slide 13: Selatogrel to prevent AMI
Selatogrel to prevent AMI A potent, fast-acting, reversible, and highly-selective P2Y12 receptor Phase 2 data presented antagonist, being developed for single • Oral presentations at the European Society of Cardiology (ESC) subcutaneous self-administration for Congress 2019, attended by the treatmen
Slide 14: Early-stage assets
Early-stage assets Compound Mechanism of Action Target Indication Status Sinbaglustat GBA2/GCS inhibitor Rare CNS diseases Phase 1 (ACT-519276) ACT-539313 Selective orexin 1 receptor antagonist Psychiatric disorders Phase 1 ACT-709478** T-type calcium channel blocker Epilepsy Phase 1 ACT-1004-1239 -
Slide 15: Engaging with the expert community
Engaging with the expert community American College of Rheumatology (ACR) Annual meeting 2019 European Society of Cardiology (ESC) ESC Congress 2019 American Academy of Sleep Medicine (AASM) / Sleep Research Society (SRS) World Sleep Society Annual SLEEP meeting 2019 World Sleep 2019 European Commit
Slide 16: Building a bright future
Building a bright future One common goal 43% 57% female male 34 nationalities Highly qualified professionals >800 employees 16 Full Year 2019 Financial Reporting | February 6, 2020
Slide 17: CFO quote on 2019 spending
“With a cost- conscious attitude and a slight shift in timelines, we spent less in 2019 than originally expected.” André C. Muller Chief Financial Officer 17 Full Year 2019 Financial Reporting | February 6, 2020
Slide 18: US GAAP net results
US GAAP net results 20 FULL YEAR in CHF millions, rounding differences may occur 19 Non-GAAP US GAAP Financial results as of Dec 31, 2019 18 Full Year 2019 Financial Reporting | February 6, 2020
Slide 19: Non-GAAP operating expenses
Non-GAAP operating expenses 20 FULL YEAR in CHF millions, rounding differences may occur 19 -54 -58 - -115 -115 -15 -215 -297 -399 -470 2018 2019 Research Development SG&A Milestones paid Non-GAAP operating expenses Financial results as of Dec 31, 2019 19 Full Year 2019 Financial Reporting | Februar
Slide 20: Cash flow
Cash flow 20 FULL YEAR in CHF millions, rounding differences may occur 19 505 35 129 5 - 8 7 2018 -17 -19 2019 -402 -473 -481 Milestones Operations Cash raise Capex Other Total received Financial results as of Dec 31, 2019 20 Full Year 2019 Financial Reporting | February 6, 2020
Slide 21: Liquidity
Liquidity 20 FULL YEAR in CHF millions, rounding differences may occur 19 @ June 2017 ∆ 2017 @ Dec 31, 2017 ∆ 2018 @ Dec 31, 2018 ∆ 2019 @ Dec 31, 2019 Financial results as of Dec 31, 2019 21 Full Year 2019 Financial Reporting | February 6, 2020
Slide 22: Financial Guidance for 2020
Financial Guidance 20 for 2020 FULL YEAR 19 Unforeseen events excluded, US GAAP operating expenses of around CHF 540 million and non-GAAP operating expenses of around CHF 500 million (both measures excluding any potential milestone payments). + + + ++ + 22 Full Year 2019 Financial Reporting | Februa
Slide 23: CEO quote on 2020 outlook
“Since the results of the daridorexant program are just months away, 2020 promises to be every bit as exciting as 2019.” Jean-Paul Clozel Chief Executive Officer 23 Full Year 2019 Financial Reporting | February 6, 2020